I lead ecosystem development and strategic partnerships for four international summits designed to accelerate innovation across high-impact verticals. My role focuses on connecting the right people — from startups and corporates to investors and public institutions — and building collaboration formats that create long-term value.
Organaid combines patient-derived 3D organoids with ImPheNet, our proprietary AI engine, to predict drug efficacy and toxicity before a compound reaches the clinic, reducing attrition, cutting timelines, and lowering development costs at the preclinical stage.
We are currently producing central nervous system organoids and, from September onwards, we will scale to industrial-level production at the Parc Científic of Barcelona (Spain), expanding our portfolio to additional organ systems and regenerative medicine.
